Home Featured Page 258

Featured

Latest

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed...

MindMed announces shareholder Meeting Results

PTSF61 – Archetypal Astrology and the Inner Healer, with Renn Butler

MYND Life Sciences Inc. Establishes Scientific Advisory Board

The Psilocybin vs. Escitalopram Trial – Part 1

Renowned Psychedelic Researcher, James Fadiman, PhD, Joins Wesana Health Scientific Advisory...

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain...

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug...

Field Trip Health Ltd. Receives Conditional Approval to Up-List to the...

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data...

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed...

MindMed announces shareholder Meeting Results

PTSF61 – Archetypal Astrology and the Inner Healer, with Renn Butler

MYND Life Sciences Inc. Establishes Scientific Advisory Board

The Psilocybin vs. Escitalopram Trial – Part 1

Renowned Psychedelic Researcher, James Fadiman, PhD, Joins Wesana Health Scientific Advisory...

PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain...

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug...

Field Trip Health Ltd. Receives Conditional Approval to Up-List to the...

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data...

EDITOR PICKS

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY